TY - JOUR
T1 - Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice
AU - Sitara, Despina
AU - Razzaque, Mohammed S.
AU - Hesse, Martina
AU - Yoganathan, Subbiah
AU - Taguchi, Takashi
AU - Erben, Reinhold G.
AU - Jüppner, Harald
AU - Lanske, Beate
N1 - Funding Information:
The authors wish to thank C. Carr for her technical help, J. Saxton for performing the histological sections, and Dr. R. Bronson for helpful discussions. This work was supported by a fund provided to BL from Harvard School of Dental Medicine.
PY - 2004/11
Y1 - 2004/11
N2 - Fibroblast growth factor-23 (FGF-23), a recently identified molecule that is mutated in patients with autosomal dominant hypophosphatemic rickets (ADHR), appears to be involved in the regulation of phosphate homeostasis. Although increased levels of circulating FGF-23 were detected in patients with different phosphate-wasting disorders such as oncogenic osteomalacia (OOM) and X-linked hypophosphatemia (XLH), it is not yet clear whether FGF-23 is directly responsible for the abnormal regulation of mineral ion homeostasis and consequently bone development. To address some of these unresolved questions, we generated a mouse model, in which the entire Fgf-23 gene was replaced with the lacZ gene. Fgf-23 null (Fgf-23 +IhI-/+IhI) mice showed signs of growth retardation by day 17, developed severe hyperphosphatemia with elevated serum 1,25(OH) 2D 3 levels, and died by 13 weeks of age. Hyperphosphatemia in Fgf-23 +IhI-/+IhI mice was accompanied by skeletal abnormalities, as demonstrated by histological, molecular, and various other morphometric analyses. Fgf-23 +IhI-/+IhI mice had increased total-body bone mineral content (BMC) but decreased bone mineral density (BMD) of the limbs. Overall, Fgf-23 +IhI-/+IhI mice exhibited increased mineralization, but also accumulation of unmineralized osteoid leading to marked limb deformities. Moreover, Fgf-23 +IhI-/+IhI mice showed excessive mineralization in soft tissues, including heart and kidney. To further expand our understanding regarding the role of Fgf-23 in phosphate homeostasis and skeletal mineralization, we crossed Fgf-23 +IhI-/+IhI animals with Hyp mice, the murine equivalent of XLH. Interestingly, Hyp males lacking both Fgf-23 alleles were indistinguishable from Fgf-23 +IhI-/+IhI mice, both in terms of serum phosphate levels and skeletal changes, suggesting that Fgf-23 is upstream of the phosphate regulating gene with homologies to endopeptidases on the X chromosome (Phex) and that the increased plasma Fgf-23 levels in Hyp mice (and in XLH patients) may be at least partially responsible for the phosphate imbalance in this disorder.
AB - Fibroblast growth factor-23 (FGF-23), a recently identified molecule that is mutated in patients with autosomal dominant hypophosphatemic rickets (ADHR), appears to be involved in the regulation of phosphate homeostasis. Although increased levels of circulating FGF-23 were detected in patients with different phosphate-wasting disorders such as oncogenic osteomalacia (OOM) and X-linked hypophosphatemia (XLH), it is not yet clear whether FGF-23 is directly responsible for the abnormal regulation of mineral ion homeostasis and consequently bone development. To address some of these unresolved questions, we generated a mouse model, in which the entire Fgf-23 gene was replaced with the lacZ gene. Fgf-23 null (Fgf-23 +IhI-/+IhI) mice showed signs of growth retardation by day 17, developed severe hyperphosphatemia with elevated serum 1,25(OH) 2D 3 levels, and died by 13 weeks of age. Hyperphosphatemia in Fgf-23 +IhI-/+IhI mice was accompanied by skeletal abnormalities, as demonstrated by histological, molecular, and various other morphometric analyses. Fgf-23 +IhI-/+IhI mice had increased total-body bone mineral content (BMC) but decreased bone mineral density (BMD) of the limbs. Overall, Fgf-23 +IhI-/+IhI mice exhibited increased mineralization, but also accumulation of unmineralized osteoid leading to marked limb deformities. Moreover, Fgf-23 +IhI-/+IhI mice showed excessive mineralization in soft tissues, including heart and kidney. To further expand our understanding regarding the role of Fgf-23 in phosphate homeostasis and skeletal mineralization, we crossed Fgf-23 +IhI-/+IhI animals with Hyp mice, the murine equivalent of XLH. Interestingly, Hyp males lacking both Fgf-23 alleles were indistinguishable from Fgf-23 +IhI-/+IhI mice, both in terms of serum phosphate levels and skeletal changes, suggesting that Fgf-23 is upstream of the phosphate regulating gene with homologies to endopeptidases on the X chromosome (Phex) and that the increased plasma Fgf-23 levels in Hyp mice (and in XLH patients) may be at least partially responsible for the phosphate imbalance in this disorder.
KW - Bone
KW - Fgf-23 null
KW - Hyp
KW - Mineralization
KW - Phosphate
UR - http://www.scopus.com/inward/record.url?scp=9644303231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9644303231&partnerID=8YFLogxK
U2 - 10.1016/j.matbio.2004.09.007
DO - 10.1016/j.matbio.2004.09.007
M3 - Article
C2 - 15579309
AN - SCOPUS:9644303231
SN - 0945-053X
VL - 23
SP - 421
EP - 432
JO - Matrix Biology
JF - Matrix Biology
IS - 7
ER -